Axial Spondyloarthritis Market Dynamics Indicate Upward Trajectory Through 2034, Reports DelveInsight

DelveInsight's "Axial Spondyloarthritis Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Axial Spondyloarthritis, historical and forecasted epidemiology as well as the Axial Spondyloarthritis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Axial Spondyloarthritis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Axial Spondyloarthritis Market Forecast
https://www.delveinsight.com/sample-request/axial-spondyloarthritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Axial Spondyloarthritis Market Report:
• The Axial Spondyloarthritis market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In January 2025, MoonLake Immunotherapeutics (Nasdaq: MLTX), a clinical-stage biotechnology company developing advanced therapies for inflammatory diseases, announced that patient screening has begun for three new trials evaluating sonelokimab, an investigational Nanobody® therapy. These trials expand the clinical program to include adolescent hidradenitis suppurativa (HS), palmoplantar pustulosis (PPP), and axial spondyloarthritis (axSpA), alongside existing studies in adult patients with HS and active psoriatic arthritis (PsA).
• In November 2024, UCB, a global biopharmaceutical company, announced new two-year data demonstrating a sustained clinical response for BIMZELX® (bimekizumab-bkzx), an IL-17A and IL-17F inhibitor, in adults with active psoriatic arthritis (PsA), active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation, and active ankylosing spondylitis (AS). These findings come from the Phase 3 studies BE OPTIMAL (PsA), BE COMPLETE (PsA), and their open-label extension BE VITAL, as well as BE MOBILE 1 (nr-axSpA), BE MOBILE 2 (AS), and their open-label extension BE MOVING.
• In September 2024, UCB, a global biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has approved BIMZELX® (bimekizumab-bkzx) for three indications: the treatment of adults with active psoriatic arthritis (PsA), active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation, and active ankylosing spondylitis (AS). BIMZELX is the first treatment approved for all three conditions, designed to selectively inhibit two key cytokines involved in inflammation-interleukin 17A (IL-17A) and interleukin 17F (IL-17F). These approvals follow its initial U.S. approval in October 2023 for moderate-to-severe plaque psoriasis in adults eligible for systemic therapy or phototherapy.
• DelveInsight estimates that the total prevalent population of axial spondyloarthritis in the 7MM was about 4,575,000 in 2023, and this number is projected to rise significantly throughout the study period from 2020 to 2034.
• A total of 3,981,346 individuals in the 7MM were overall prevalent for axSpA. Throughout the prediction period (from 2024 to 2034), it is expected that these cases will rise
• DelveInsight's estimates indicate that the total prevalent population of axial spondyloarthritis in the 7MM was around 4,575,000 in 2023, with a significant increase expected during the study period from 2020 to 2034.
• According to DelveInsight's estimates, the total diagnosed population of non-radiographic axial spondyloarthritis in the US was approximately 569,000 cases in 2023.
• In 2023, Germany had the highest number of prevalent axial spondyloarthritis cases among the EU4 and UK countries, with Spain following closely behind.
• Key Axial Spondyloarthritis Companies: Janssen Pharmaceuticals, Pfizer, UCB Biopharma, Celgene, Inmagene Biopharmaceuticals, Galapagos NV, Kyowa Kirin Co., Ltd., Eli Lilly and Company, Merck Sharp & Dohme LLC, Pfizer, Novartis, Jiangsu HengRui Medicine, UCB Biopharma, and others
• Key Axial Spondyloarthritis Therapies: SIMPONI (golimumab), XELJANZ (tofacitinib), Bimekizumab, CC-99677, ABY- 035, Filgotinib, KHK4827, Ixekizumab, Golimumab, etanercept, Secukinumab, SHR0302, Certolizumab Pegol, and others
• The Axial Spondyloarthritis epidemiology based on gender analyzed that the prevalent population of Axial Spondyloarthritis showed a male predominance, whereas, nr-axSpA showed female predominance.
• The Axial Spondyloarthritis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Axial Spondyloarthritis pipeline products will significantly revolutionize the Axial Spondyloarthritis market dynamics.

Axial Spondyloarthritis Overview
Axial Spondyloarthritis is a type of chronic inflammatory arthritis primarily affecting the spine and the sacroiliac joints, which connect the lower spine to the pelvis. This condition can lead to pain, stiffness, and decreased mobility in the affected areas. AxSpA encompasses two subtypes: non-radiographic axial spondyloarthritis (nr-axSpA), where there is no visible damage on X-rays, and ankylosing spondylitis (AS), where changes are visible on X-rays, including possible fusion of the vertebrae.

Get a Free sample for the Axial Spondyloarthritis Market Report:
https://www.delveinsight.com/report-store/axial-spondyloarthritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Axial Spondyloarthritis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Axial Spondyloarthritis Epidemiology Segmentation:
The Axial Spondyloarthritis market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Axial Spondyloarthritis
• Prevalent Cases of Axial Spondyloarthritis by severity
• Gender-specific Prevalence of Axial Spondyloarthritis
• Diagnosed Cases of Episodic and Chronic Axial Spondyloarthritis

Download the report to understand which factors are driving Axial Spondyloarthritis epidemiology trends @ Axial Spondyloarthritis Epidemiology Forecast
https://www.delveinsight.com/sample-request/axial-spondyloarthritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Axial Spondyloarthritis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Axial Spondyloarthritis market or expected to get launched during the study period. The analysis covers Axial Spondyloarthritis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Axial Spondyloarthritis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Axial Spondyloarthritis Therapies and Key Companies
• SIMPONI (golimumab): Janssen Pharmaceuticals
• XELJANZ (tofacitinib): Pfizer
• Bimekizumab: UCB Biopharma
• CC-99677: Celgene
• ABY- 035: Inmagene Biopharmaceuticals
• Filgotinib: Galapagos NV
• KHK4827: Kyowa Kirin Co., Ltd.
• Ixekizumab: Eli Lilly and Company
• Golimumab: Merck Sharp & Dohme LLC
• etanercept: Pfizer
• Bimekizumab: UCB Biopharma
• Secukinumab: Novartis
• SHR0302: Jiangsu HengRui Medicine
• Certolizumab Pegol: UCB Biopharma

Discover more about therapies set to grab major Axial Spondyloarthritis market share @ Axial Spondyloarthritis Treatment Market
https://www.delveinsight.com/sample-request/axial-spondyloarthritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Axial Spondyloarthritis Market Drivers
• The introduction of novel products
• Increasing prevalence
• Awareness about the Disease
• Research and development strategies

Axial Spondyloarthritis Market Barriers
• High-cost treatment
• Delay in Diagnosis
• Immunogenicity
• Loss of patent exclusivity
• Availability of generics
• Poor Quality of Life

Scope of the Axial Spondyloarthritis Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Axial Spondyloarthritis Companies: Janssen Pharmaceuticals, Pfizer, UCB Biopharma, Celgene, Inmagene Biopharmaceuticals, Galapagos NV, Kyowa Kirin Co., Ltd., Eli Lilly and Company, Merck Sharp & Dohme LLC, Pfizer, Novartis, Jiangsu HengRui Medicine, UCB Biopharma, and others
• Key Axial Spondyloarthritis Therapies: SIMPONI (golimumab), XELJANZ (tofacitinib), Bimekizumab, CC-99677, ABY- 035, Filgotinib, KHK4827, Ixekizumab, Golimumab, etanercept, Secukinumab, SHR0302, Certolizumab Pegol, and others
• Axial Spondyloarthritis Therapeutic Assessment: Axial Spondyloarthritis current marketed and Axial Spondyloarthritis emerging therapies
• Axial Spondyloarthritis Market Dynamics: Axial Spondyloarthritis market drivers and Axial Spondyloarthritis market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Axial Spondyloarthritis Unmet Needs, KOL's views, Analyst's views, Axial Spondyloarthritis Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.